

Appointment of Lucid Health Consulting to underpin product registration and reimbursement strategy

- **Lucid Health Consulting ('LHC') appointed to assist Tryp in advancing product registration and reimbursement strategy for TRP-8803 (IV-infused psilocin), which may improve efficacy, safety and patient experience**
- **Lucid Health Consulting are a leading advisory group focused on providing expert advice in health economics, pricing and reimbursement, market access and regulatory affairs**
- **Engagement will commence in the coming weeks and aim to advance TYP's strategy to register TRP-8803 in the Australian market**
- **Appointment provides TYP with the ability to leverage LHC's experience and track record to define the fastest possible regulatory and market access route**
- **TRP-8803's potential advantages include a significant reduction in onset of the psychedelic state, more precise control of the depth and duration of the experience and a reduction in the duration of the intervention to a commercially feasible timeframe**
- **LHC to assist with ongoing data collection and engagement with the Therapeutic Goods Administration (TGA)**

Perth, Australia – Tryptamine Therapeutics Limited ('Tryp' or the 'Company') (ASX: TYP), a clinical-stage biotechnology company focused on the development of an innovative and scalable intravenous-infused psilocin formulation which may be used in conjunction with psychotherapy to address significant unmet medical needs, is pleased to advise that it has appointed Australian-based Lucid Health Consulting ('LHC') to assist the Company with its product registration and reimbursement strategy for TRP-8803 (IV-infused psilocin) in the Australian market.

LHC are providers of expert advice in health economics, pricing and reimbursement, market access and regulatory affairs in Australia. The group enables companies to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.

As part of the engagement which will commence 1 July 2024, LHC will assist the Company to advance product registration and reimbursement opportunities in the Australian market. This will include Tryp's ongoing engagement with the Therapeutic Goods Administration (TGA).

The Company has made the strategic decision to appoint LHC due to the group's experience and strong track record in the Australian market, which is underpinned by a leading team of experts who have held roles with large international drug development companies including Johnson & Johnson, Janssen Australia and Schering-Plough amongst others.

The Company looks forward to working alongside LHC to define and advance its strategy, which will be underpinned by a number of upcoming clinical trials utilising TRP-8803. Additional updates will be provided to shareholders as developments materialise.

Management commentary:



LHC Director and Partner, Mr. George Papadopoulos said: *"We are pleased and excited to be chosen by Tryp for this strategic collaboration. LHC looks forward to assisting Tryp advance the pathway to market for their proprietary TRP-8803 treatment.*

"The proprietary IV infused synthetic psilocin that is TRP-8803, is an exciting advancement in the field, and we look forward to working with Tryp to ensure the fastest possible regulatory and market access is achieved, so patients can equitably access this innovative treatment."

Tryp Chief Executive Officer, Mr. Jason Carroll said: *"We are pleased to announce this strategic collaboration with Lucid Health Consulting, which followed an extensive period of engagement between the parties. As part of our development strategy, the Tryp management team continuously appraises opportunities to partner with best-in-class specialists who can help advance the pathway to market for the Company's proprietary TRP-8803 treatment.*

"With the strength of its leadership team and track record in the Australian market, LHC is an established leader in its field which can provide targeted assistance to Tryp in key areas of development, including regulatory engagement and product pricing. We look forward to working with experts of Lucid Health's calibre as we jointly pursue the advancement of an improved solution for the application of psilocin treatments."

For more information, please visit www.trypterapeutics.com.

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

Investor & Media Contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@trypterapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Forward-Looking Information

Certain information in this news release, including statements relating to the anticipated completion of the Arrangement and the holding of the annual and special meeting of Tryp's securityholders, constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information,



including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.